Pacific BiosciencesPACB
About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Employees: 796
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
33% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]
17% more capital invested
Capital invested by funds: $337M [Q2] → $395M (+$58.6M) [Q3]
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
0% less funds holding
Funds holding: 226 [Q2] → 225 (-1) [Q3]
9% less call options, than puts
Call options by funds: $3.32M | Put options by funds: $3.63M
5.02% less ownership
Funds ownership: 90.3% [Q2] → 85.28% (-5.02%) [Q3]
13% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 77
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
UBS John Sourbeer 25% 1-year accuracy 2 / 8 met price target | 22%upside $2 | Neutral Downgraded | 11 Nov 2024 |
Scotiabank Sung Ji Nam 60% 1-year accuracy 12 / 20 met price target | 266%upside $6 | Sector Outperform Maintained | 11 Nov 2024 |
Piper Sandler David Westenberg 67% 1-year accuracy 26 / 39 met price target | 52%upside $2.50 | Neutral Maintained | 11 Nov 2024 |
Financial journalist opinion
Based on 10 articles about PACB published over the past 30 days
